November 14, 2003 - ASM Letter to Medicare Conferees The ASM sent a letter to House and Senate Medicare Conferees urging them to oppose cuts that would adversely affect clinical laboratories, such as co-payments for laboratory testing, a freeze on cost of living adjustments to Medicare payments laboratory services, and/or further reductions in the reimbursement of laboratory tests covered by Medicare.
October 13, 2003 - ASM Letter Regarding Increasing Funding for the EPA Research Programs The ASM sent a letter to Senator Christopher Bond (R-MO), Chair of the Appropriations Subcommittee on Veterans Affairs and Housing and Urban Development and Independent Agencies and Senator Barbara Mikulski (D-MD), ranking member recommending increased funding for EPA research programs in the FY 2004 appropriations bill. ASM sent a similar letter to the House Subcommittee Chair, Representative James Walsh (R-NY) and Ranking member Representative Alan B. Mollohan (D-WV).
August 14, 2003 - ASM Assists CLIAC with Information on DTM Culture Media PSAB's Committee on Laboratory Practices responded to a request from the Clinical Laboratory Improvements Advisory Committee (CLIAC) regarding ASM's position on exempting dermatophyte culture media (DTM) from end-user quality control (QC) under the Clinical Laboratory Improvement Amendments (CLIA) regulations.
June 30, 2003 - ASM Sends Letter to Powell Regarding Visa Issues On June 30, 2003 the ASM wrote to Secretary Colin Powell to ask the Department of State develop procedures and allocate resources necessary to assure prompt and appropriate action on visa requests for students and researchers seeking to study the microbiological sciences within the United States.
April 11, 2003 - ASM Comments on QC/Laboratory Director Draft Guidelines PSAB's Committee on Professional Affairs submitted comments to the Centers for Medicare and Medicaid Services (CMS) on itsdraft copy of the revised Interpretive Guidelines, Appendix C of the StateOperationsManual, which applies to the CLIA regulations on quality control and laboratory director requirements that were published in the Federal Registeron January 24, 2003.
January 22, 2003 - FDA Guidance Document on CJD/vCJD The ASM's Committee on Laboratory Practices submitted comments on the Food and Drug Administration's Draft "Guidance Document for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)."